British Journal of Haematology · 2022 · 14 citations · 24 references
MedicineHematologyOncologyCancer ImmunologyHematologic OncologyTumor ProgressionHematologic MalignanciesLymphoid TumorsRelapsed DiseaseLymphoid Neoplasm PrognosisLymphoma RelapseMedian AgePrognostic Factors AnalysisRelapsed Lymphoid Neoplasms
Although follicular lymphoma (FL) patients relapsing within 24 months after first-line treatment (POD24) have a poor prognosis, some cases show notable survival after first relapse (SF1R). We aimed to characterize the POD24 FL population and to identify the main prognostic factors at progression. We selected 162 POD24 patients (80F; median age at first relapse 59 years) from a cohort of 1067 grades 1-3a FL-treated patients. The remaining 905 patients treated with first-line immunochemotherapy and diagnosed during the same period were used to compare outcomes in terms of survival. After a median follow-up of 11.0 years, 96 patients died (10y-SF1R of 40%). Age over 60 years (p < 0.001), high lactate dehydrogenase (LDH) (p < 0.001), haemoglobin (Hb) less than 120 g/L (p < 0.001), advanced stage (p < 0.001), high-risk Follicular Lymphoma International Prognostic Index (FLIPI) (p < 0.001), histological transformation (HT) (p < 0.001) and reaching less than complete response (CR) after salvage therapy (p < 0.001), predicted poor SF1R at relapse. In multivariate analysis only high-risk FLIPI and HT maintained prognostic significance for SF1R. POD24 patients not transformed and with low/intermediate FLIPI at relapse behaved better than the remaining cases. POD24 patients showed an excess mortality of 38% compared to the general population. Although outcome of POD24 FL patients is poor, a considerable group of them (low/intermediate FLIPI and not transformed at first relapse) behave better.
24
Gilles Salles, John F. Seymour, Fritz Offner et al. · The Lancet · 2010 · 1.1K citations
Carla Casulo, Michelle Byrtek, Keith Dawson et al. · Journal of Clinical Oncology · 2015 · 844 citations · Full text
Medicine, Immunology, Oncology +11
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Robert Marcus, Andrew Davies, Kiyoshi Ando et al. · New England Journal of Medicine · 2017 · 788 citations · Full text
Medicine, Immunology, Oncology +14
Massimo Federico, Monica Bellei, Luigi Marcheselli et al. · Journal of Clinical Oncology · 2009 · 751 citations · Full text